Letermovir and maribavir for the treatment and prevention of cytomegalovirus infection in solid organ and stem cell transplant recipients
from Clinical Infectious Diseases
Until recently, available drugs for cytomegalovirus prevention and treatment in transplant patients included (val)ganciclovir, foscarnet, and cidofovir. Use of these drugs is limited by toxicity and the development of resistance. The 2017 approval of letermovir for prevention of CMV after stem cell transplant marked the first approval of an anti-CMV agent since 2003.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063